openPR Logo
Press release

Tyrosine Kinase Inhibitors - Pipeline Insights 2017

10-13-2017 08:22 AM CET | Health & Medicine

Press release from: Arizton Advisory & Intelligence

Pharma Pipeline Analysis by Arizton Advisory & Intelligence

Pharma Pipeline Analysis by Arizton Advisory & Intelligence

The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline tyrosine kinase inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides detailed information about discontinued and dormant drugs.

The report profiles key players in developing potential tyrosine kinase drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Scope

Provides in-depth insights about active Tyrosine kinase inhibitors pipeline drug candidates

Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery

Provides pipeline assessment by monotherapy, combination therapy products, and route of administration

Provides comparative analysis of key marketed and pipeline Tyrosine kinase inhibitors

Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development partner

Analyzes key players involved in clinical research and development of the Tyrosine Kinase inhibitors

Provides the coverage of key news related to Tyrosine kinase inhibitors, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Tyrosine kinases are a subclass of protein kinase. Tyrosine kinases play a central role in signal transduction that ultimately affects gene transcription within the nucleus. These molecules are considered as pivotal points of functional cellular pathways as they control cell cycle, proliferation, differentiation, and cell death or survival. Tyrosine kinases are primarily classified as receptor tyrosine kinase (RTK) which inlcude EGFR, PDGFR, FGFR and the IR and non-receptor tyrosine kinase (NRTK) which include SRC, ABL, FAK and Janus kinase. Disruption in tyrosine kinase pathway is implicated in several malignancies and thus tyrosine kinase inhibitors, targeted drug molecules inhibiting tyrosine kinase activity, are considered as a key therapeutic class. Few of the key marketed tyrosine kinase inhibitors include Dasatinib (Sprycel), Erlotinib (Tarceva), Gefitinib (Iressa), Imatinib (Gleevec). Lapatinib (Tykerb), Nilotinib (Tasigna), Sorafenib (Nexavar), Sunitinib (Sutent).

Over the past two decades, research studies have proved its efficacy for mitigation and control of non-cancerous diseases too. Thus research activity on use of inhibitors for various diseases such as Parkinson's disease and chronic obstructive pulmonary disorder is gradually increasing. The growing availability of these agents has enabled the pharmaceutical companies to develop new combination molecules which have the capacity to provide greater insight into the body’s acceptance of inhibitors so as to develop more effective therapies.

More recently, few molecules have been developed that inhibits tyrosine kinase these agents are in various stages of clinical development. The tyrosine kinase inhibitors pipeline has more than 15 molecules and is expected to achieve the regulatory approval in the near future, few of which are Oncoprex (CNVN202), ORS-1006, JNJ 49095397, RV-568, AP32788, APTO-500, and transtinib. In pipeline analysis, these are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-Clinical stage. Few of the companies which are involved in the development of tyrosine kinase inhibitor include IL-Yang Pharm, SRI, Sareum, Genprex, Arrien, J&J, and Takeda.

Reasons to Buy

To gain erudite insights about the Tyrosine Kinase inhibitor pipeline landscape

To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine

To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market

To identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain informed updates on drug termination/drug discontinuation

Related Reports

1) Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/chimeric-antigen-receptor-car-t-cell-immunotherapy-pipeline-insights-2017

2) Bruton's Tyrosine Kinase (BTK) Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/brutons-tyrosine-kinase-btk-inhibitors-pipeline

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Kinase Inhibitors - Pipeline Insights 2017 here

News-ID: 771641 • Views: 1074

More Releases from Arizton Advisory & Intelligence

Lubricants: The High-Performance Engine's Lifeline
Mineral-based lubricants are the most commonly used lubricants among the various types of lubricants, which include solid, semi-solid, and liquid lubricants. Lubricants are used to minimize friction and wear and tear between surfaces. Most lubricants consist of 70% lubricant oil and up to 30% chemical compounds known as additives. The lubricants industry is steadily moving towards environmental sustainability and preserving natural resources. The industry is driven by factors such as: Increasing
Water Softeners To be Sold More Through Offline Distribution Channels
The rising demand for water treatment in countries such as China, India, and Singapore are expected to propel the demand for water softeners in the near future. According to a recent report, Water Softener Market - Global Outlook & Forecast 2022-2027, by Arizton, The global water softener market is expected to reach USD 5.7 million by 2027. Consumers are increasingly conscious of hard water and are seeking products that help in
Is Deployment of Smart Connectivity Leading the Digital Lock Market?
According to the latest Arizton's market research report, the digital lock market size to cross over USD 1,497.96 million by 2026, growing at a CAGR of 11.98% during the forecast period. US Digital Lock Market Growth The demand for Bluetooth smart locks is increasing rapidly in the US, which is driving the growth of the market. The smart city initiative by the US government and the rising focus on adopting smart technologies
Is COVID-19 Impacting the Growth of the Digital Pathology Market Positively?
According to the latest Arizton's market research report, the digital pathology systems market size to reach USD 1277.64 million by 2026, growing at a CAGR of 10.43% during the forecast period. Global Digital Pathology Systems Market Growth Digital pathology is referred to as a revolutionary and cutting-edge technology. The adoption of AI and automation in the process is minimizing the requirement of human labor to manage digital pathology devices and the interface.

All 5 Releases


More Releases for Tyrosine

Tyrosine Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Tyrosine Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 102 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/global-tyrosine-market_p130094.html   Scope of the Report: The worldwide market for Tyrosine is
Glycyl Tyrosine Market SWOT Analysis 2018-2023
Future Market Reports on Global Glycyl Tyrosine 2018 Research Report presents a professional and complete analysis of Global Glycyl Tyrosine Market on the current market situation. The Global Glycyl Tyrosine Market 2018 report includes Glycyl Tyrosine market Revenue, market Share, Glycyl Tyrosine industry volume, market Trends, Growth aspects. It analyses the important factors of the Glycyl Tyrosine market based on present industry situations, Glycyl Tyrosine market demands, business strategies utilized
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Tyrosine Market Professional Survey Report 2017-2022
About Tyrosine Market This report studies Tyrosine in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. Access Full Report: https://www.reportsandmarkets.com/reports/global-tyrosine-market-professional-survey-report-2017-1623090 This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Ajinomoto Evonik KYOWA Tianjin Tianan Pharmaceuticals Hubei Bafeng Pharmaceutical Jinghai Amino Acid JIRONG PHARM ChuyuanGroup Siwei Amino Acid SHINE STAR(HUBEI)BLOLOGICAL On
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Tyrosine Market Trends and 2022 Forecast
ReportsWeb.com has announced the addition of the “United State Tyrosine 2022 Market Research Report” The report focuses on United State major leading players with information such as company profiles, product picture and specification. United States Tyrosine market competition by top manufacturers/players, with Tyrosine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including Ajinomoto Evonik KYOWA Tianjin Tianan Pharmaceuticals Hubei Bafeng Pharmaceutical Jinghai Amino Acid JIRONG PHARM ChuyuanGroup Siwei Amino Acid SHINE STAR (HUBEI) BLOLOGICAL For